Sam Fazeli

One of my favorite in the Henleus Fosun Pharma world is Serplulimab.

And I learned a lot more about this at the latest WCLC conference, World Conference on Lung Cancer, than before.

The first thing I learned also is that it is the highest ranked product for small cell lung cancer in Europe by ESMO.

And this is completely home developed, if I'm not wrong.

So I'm interested in the story of serplulimab.

It is a PD-1 checkpoint inhibitor.

And I've seen head-to-head data that looks really exciting and interesting.

And of course, you've got this bridging study that you already spoke about in small cell lung cancer in the US.

It's literally going up against the standard of care, which is dyscentric plus chemo.

So I'm interested in the story of this molecule and what your ambitions for it are.

When I searched around, I didn't find too many other indications being tested out.

But just tell us a little bit about this and when we should expect data and what its history is, because it is one of those situations where a molecule was discovered that is better than what's, at least in this indication.

Well, that's a good ambition to have, right?

Yeah.

I think maybe your other ambition should be to get a standing ovation when you present the data.

That's one of the things that companies seem to obviously enjoy.

Now, what's interesting, of course, is that PD-1 inhibitors, as you said, have not succeeded in small cell lung cancer.

PD-L1, which is not usually the story.

Usually PD-L1s tend to beat out the PD-L1 inhibitors.

And part of the argument is, although I've not really been able to 100% verify this, I don't think anybody can put their hand on their heart and say it's absolutely because the PD-1 inhibitor inhibits both PD-L1 and PD-L2.